The Black Man’s Cardiovascular Inheritance

1 in 63. What the data means, where it comes from, and what to do with it

I was born in Nairobi. I trained in medicine in Kenya, where the concept of the strong, stoic provider-man is not exclusively American — it is East African, West African, and it crosses the diaspora with the men who carry it. I came to the United States to pursue cardiology fellowship, and over two decades of clinical practice, I have treated patients on two continents, across cultures, across income levels, and across a health system that treats men of different races with measurably different outcomes. I have also sat in enough catheterization labs, looked at enough angiograms, and attended enough family conversations after events that should not have happened to a 47-year-old man to understand something with the full weight that it deserves: Black men in the United States are experiencing a cardiovascular crisis that is not adequately named, not adequately responded to, and not adequately represented in the clinical voice that reaches men who could act before the crisis reaches them.

So this chapter is a direct conversation. Not a lecture. Not a lament. A clinical conversation between a cardiologist who was not born here and a population of men I serve with particular commitment — because the physiology, the culture, and the structural context all require it, and because the data demands that someone with the credential and the proximity say it plainly.

The numbers I am about to give you are not comfortable. They are not comfortable because they are real. After each one, I will tell you what can be done — because the purpose of confronting the data is not to overwhelm the reader but to equip him.

The Numbers in Full

Let me begin with a statistic that is precise enough to carry weight.

A 2025 study published using 2022 National Vital Statistics System data, available in the peer-reviewed literature through PMC11954819, calculated the cumulative risk of cardiometabolic death before age 45 among Black men who were 25 years old. The number: one in 63. The comparable figure for White men of the same starting age: one in 142. The disparity ratio is approximately 2.3 to 1.

Take a moment with that number. If you are a Black man reading this and you are 25, 30, 35, 40 years old, and you look at the men in your generation — your friends, your colleagues, your brothers — that is the probability distribution operating underneath. One in sixty-three will die of a cardiometabolic cause before age 45. Not eventually. Before 45.

Between 2000 and 2022, Black Americans experienced 779,387 excess cardiovascular deaths — deaths beyond what would have been expected if Black Americans had the same age-adjusted cardiovascular mortality rate as White Americans. The source is a landmark JACC 2024 study by Arun, Sawano, Caraballo, Yancy, Krumholz and colleagues, published on the eve of Juneteenth. Of those 779,387 excess deaths, 416,500 were Black men — representing 12.5 million excess years of potential life lost over those 22 years. That is more than 37,000 preventable cardiac deaths among Black men per year, every year, for two decades.

The age-adjusted CVD mortality rate for non-Hispanic Black males in 2023 was 360.1 per 100,000 — versus 218.3 per 100,000 for all U.S. individuals. Black men carry the highest cardiovascular mortality rate of any sex-race combination in the country. Sixty-three percent of non-Hispanic Black males have some form of cardiovascular disease, compared to 48.9% of all U.S. adults.

I give you these numbers not to produce despair. I give them to you because they are your clinical context, and knowing your clinical context is the foundation of every intervention that can change it.

Hypertension: The Dominant Mechanism

If I were to identify the single most important modifiable cardiovascular risk factor in this population, it is blood pressure. The data is unambiguous.

According to the AHA’s 2026 Black CVD Fact Sheet, 62.3% of non-Hispanic Black males aged 20 and older have hypertension, defined as systolic blood pressure ≥130 mmHg or current antihypertensive medication use. The comparable figure for all U.S. adults is 47.3%. Hypertension-related mortality for Black men stands at 65.0 deaths per 100,000 — versus 31.9 per 100,000 for all U.S. individuals.

Importantly, Black men develop hypertension earlier. A 2019 study by Pencina and colleagues in JAMA Cardiology calculated lifetime hypertension risk and found that Black men and women develop hypertension earlier in life, with higher severity at each age, than White peers. By the time hypertension is detected, in many cases it has been operating for years without clinical contact.

And the blood pressure control rate tells the story of a system that is failing these men after the diagnosis: according to CDC data, only 25% of Black adults recommended to take antihypertensive medication have their blood pressure controlled — versus 32% of non-Hispanic White adults. This gap is not about willingness. It is about access, trust, physician time, medication side effect communication, and the specific ways that the healthcare system makes follow-through difficult for men who work long hours, often in multiple jobs, in communities with fewer cardiovascular specialists.

There are more than 16.8 million Black Americans living in counties with limited or no cardiology care — what the Association of Black Cardiologists calls “cardiology deserts.” More than 2 million live in areas with no cardiologist at all. This is not a personal failure of any individual Black man. It is an infrastructure failure with cardiovascular consequences.

Why Earlier Onset Matters

One of the features of Black men’s cardiovascular disease that receives insufficient clinical attention is not the absolute rate but the timing. Black men develop cardiovascular disease younger, with less clinical warning, and with more severe initial presentations.

In the CARDIA study — the Coronary Artery Risk Development in Young Adults cohort — 26 of 27 incident heart failure cases in individuals under 50 years of age were among Black participants. That is not a statistical fluctuation. That is a distribution so skewed it describes a different clinical trajectory.

Black men have approximately twice the incidence of sudden cardiac death as White men — an annual SCD incidence of approximately 0.18% per year in Black men versus 0.07% per year in White men. Black SCD patients are more than six years younger on average than White SCD patients. When sudden cardiac death is the first clinical presentation of cardiovascular disease, the window for intervention has already closed.

This is why screening in Black men cannot follow the conventional age-based algorithm that was calibrated on predominantly White study populations. The timeline is different. The preventive window is shorter. The CAC score and ApoB that are considered reasonable to check at 50 in an average-risk White man may need to be checked at 40 in a Black man with any family history of premature cardiac disease.

The Race-Stress Interaction — The Weathering Hypothesis

I want to be careful here. I am a cardiologist, not a sociologist, and I am going to speak in the language I know: physiology and evidence. But the physiology requires an accurate account of what produces it.

In 1992, Arline Geronimus, a public health researcher at the University of Michigan, proposed what she called the weathering hypothesis: that African Americans experience early health deterioration as a consequence of the cumulative impact of repeated experience with social or economic adversity and political marginalization. The physiological mechanism she proposed was allostatic load — the cumulative biological wear from sustained high-effort coping with chronic stressors that the body’s stress-response systems were not designed to bear indefinitely.

By 2006, she and her colleagues had validated this in biomarker data. A 2006 study in the American Journal of Public Health found that Black adults showed significantly higher allostatic load scores — measuring cortisol patterns, inflammatory markers, blood pressure, and metabolic indices — at younger ages than their White peers. The pattern was consistent across socioeconomic strata. It was not simply a poverty effect. It was observed in middle-class and educated Black adults as well. The weathering was a function of navigating, chronically and with high effort, a social environment in which race-based adversity operated as a persistent background stressor.

As a cardiologist, I translate this into the physiology we have discussed throughout this book: the HPA axis under chronic load, cortisol patterns that disrupt sleep and drive visceral adiposity, sympathetic activation that elevates resting heart rate and blood pressure, inflammatory cytokines that damage the vascular endothelium. The weathering hypothesis is not a metaphor. It describes a specific biological mechanism for why a Black professional man in his late 30s can have the cardiovascular age of a 50-year-old White peer — despite better diet, despite gym attendance, despite all the choices that are supposed to make a difference.

What produces that trajectory is not genetics. It is not individual behavior. It is the physiological cost of a lifetime of operating with full capability in a system that was not built with your success as its design objective.

David Williams at Harvard has documented this extensively. In published reviews of racism and health, Williams and colleagues have demonstrated that experiences of racial discrimination are independently associated with pre-clinical indicators of disease — elevated cortisol dysregulation, accelerated coronary artery calcification, and elevated blood pressure — through the same autonomic and inflammatory pathways that chronic work stress activates. The experience of discrimination is not a psychological harm that stays in the psychological domain. It translates into measurable cardiovascular biology.

The Institute of Medicine’s landmark 2003 report Unequal Treatment documented that racial and ethnic minorities receive lower-quality healthcare even after controlling for insurance status, income, and clinical severity — including being less likely to receive appropriate cardiac medication and less likely to undergo coronary revascularization. A 2024 follow-up review concluded that twenty years after the original report, unequal treatment persists. The man reading this chapter has been navigating a healthcare system that, on average, provides him with less than it provides his White peers — even when his insurance and income are equivalent.

The African Continental Context — and the Diaspora-Specific Risk Profile

I want to speak for a moment to the men who, like me, arrived in this country from Africa.

There is a cardiovascular risk gradient that follows migration in ways that are often counterintuitive. In sub-Saharan Africa, the WHO AFRO region reports cardiovascular disease as the leading cause of non-communicable disease mortality, with an estimated 36% hypertension prevalence and more than 57% of those hypertensive individuals undiagnosed. The African man who emigrates to the United States does not leave his cardiovascular risk behind — he may, in fact, acquire additional risk layers through the acculturation process.

The so-called healthy immigrant paradox — whereby recent arrivals to the United States have better health outcomes than US-born citizens — erodes over time as dietary patterns shift toward the American high-processed-food norm, as physical activity patterns change, as chronic stress from professional assimilation compounds, and as the protective social networks of the origin community are replaced with thinner American social ties. Studies of African and Caribbean immigrant men consistently show that hypertension prevalence approaches US-born Black male rates within a generation.

The African immigrant professional man carries a specific combination of risks: the cardiovascular profile of his origin country modified by the dietary and lifestyle shifts of American professional life, layered over the allostatic load of immigration and acculturation, and embedded in a healthcare system that, as Unequal Treatment documents, may treat him as a statistic rather than a person. He may arrive healthy. He may assume, for years, that the health he brought with him is the health he has now.

I have watched this trajectory in my clinic. The man who left Lagos or Nairobi or Accra healthy and hardworking, who built a career in Houston or Chicago or Atlanta, and who presents at 54 with a myocardial infarction and a blood pressure that has been elevated for eight years without treatment, because he trusted his health history rather than getting it checked.

The Lp(a) Factor — Genetic Risk That Demands Specific Attention

There is one genetic cardiovascular risk factor that is disproportionately prevalent in people of African descent and is almost never discussed in this population with the directness it deserves: Lp(a), or lipoprotein(a).

Lp(a) is an LDL-like particle carrying an additional apolipoprotein(a) tail that promotes both atherosclerosis and thrombosis. Its concentration is approximately 80% heritable — meaning it is largely set by genetics and is not meaningfully modifiable by diet, exercise, statin therapy, or lifestyle changes. Elevated Lp(a) (above approximately 50 mg/dL or 125 nmol/L) is present in roughly 20% of the general population. In individuals of African descent, the prevalence of elevated Lp(a) is higher — some studies estimate 25-35% — and the specific isoforms present may carry greater atherogenic potential.

This matters because Lp(a) is not measured on a standard lipid panel. A man can have a completely normal LDL, a normal ApoB, and an Lp(a) of 300 nmol/L — nearly three times the risk threshold — and never know it. Lp(a) is one test, done once. The level does not change substantially over a lifetime. It costs approximately $30-50 when ordered by a physician.

If you are a Black man reading this chapter, Lp(a) should be on your list. Not as a catastrophizing exercise — knowing a high Lp(a) does not mean you will have a cardiac event, and it does not mean there is nothing to be done. It means you should be on more aggressive LDL-lowering therapy, should pursue earlier imaging (CAC scoring, coronary CTA), and should be considered for Lp(a)-specific RNA therapeutics if they become available through ongoing clinical trials. Knowing your Lp(a) status places you in an informed position. Not knowing it places you at the mercy of a risk you cannot manage.

Medical Mistrust — Data, Not Narrative

I will not pretend this chapter can address medical mistrust in a paragraph. But I can be clear about what the data shows.

KFF/The Undefeated Survey found that Black adults are 19 percentage points less likely to trust doctors than White adults, and 14 points less likely to trust local hospitals. A 2024 Pew Research survey found that 44% of Black men believe the U.S. healthcare system was designed to hold Black people back. These are not irrational perceptions. They are responses to documented historical facts — the Tuskegee Syphilis Study, centuries of non-consensual medical experimentation on enslaved bodies, and the ongoing pattern documented in Unequal Treatment of differential care quality for Black patients.

And yet — this is the critical nuance, supported by 2025 research that contradicts a persistent stereotype — Black men are not passive avoiders of healthcare. Recent evidence shows that Black men are active users of health services and strive to remain healthy for themselves and their families. The issue is not absence of motivation. It is what happens inside the system when they arrive: shorter visits, faster speech, fewer rapport-building statements, differential prescription rates. The problem is not a Black man’s relationship to his own health. It is a system’s relationship to him.

The clinical implication for any Black man reading this: you are not the system’s failure to fix. You are a man with specific, quantifiable, addressable cardiovascular risk who deserves the same quality of investigation that any other man with your risk profile deserves — and who, by the data, is less likely to receive it unless you ask for it specifically. This book is part of equipping you to ask.

The Faith Community as a Clinical Partner

The Black church in America is the most trusted institution in Black American community life, and it has a long and documented history of serving as a site for health communication and intervention that reaches men who are not otherwise reachable through conventional healthcare channels.

The African Methodist Episcopal Church’s International Health Commission (amechealth.org) runs cardiovascular screening programs, has partnerships with the American Heart Association and the Association of Black Cardiologists, and has designated July as Faith Based Health Month with specific cardiovascular screening initiatives. The Church of God in Christ, the National Baptist Convention, and COGIC all participate in faith-based health coalition work that has reached hundreds of thousands of Black men with blood pressure screening, diabetes testing, and cardiovascular risk counseling.

I want to acknowledge the theological framing that is authentic to many of the men in this population: the body as stewardship. 1 Corinthians 6:19-20 speaks of the body as a temple. This is not merely a metaphor in the tradition of these churches — it is a serious theological claim with practical implications. Caring for your cardiovascular health is not vanity. It is stewardship of what you have been given to carry. If this framing is yours, I am not appropriating it. I am recognizing that it is a more powerful motivator for some men than mortality statistics, and that both are accurate.

The Clinical Response That Works

I want to be direct here, because this chapter has been heavy with data that could feel like a verdict. It is not a verdict. Every link in the chain I have described is modifiable.

Blood pressure can be controlled. The ALLHAT trial, the largest antihypertensive trial ever conducted, was powered specifically to examine outcomes in Black patients. Chlorthalidone (a thiazide-type diuretic) was found to be superior to other first-line antihypertensives for reducing heart failure in Black patients. Calcium channel blockers were superior to ACE inhibitors for reducing stroke. The evidence exists. The treatments work. The question is whether the man gets to the appointment and whether the appointment leads to treatment and follow-up.

ApoB, Lp(a), and advanced lipid testing provide the most accurate picture of atherogenic risk. A Black man with a normal LDL who believes his cholesterol is fine may be missing a significant ApoB burden or a substantial Lp(a). These tests cost approximately $30-80 combined through direct-access laboratories and require a physician order or a direct-access lab service.

CAC scoring provides a direct, non-invasive measure of atherosclerotic burden. Given that Black men develop disease earlier and with less warning, a CAC score at 38-42 rather than 50 is clinically defensible if any risk factors are present.

The REGARDS cohort (Reasons for Geographic and Racial Differences in Stroke), which enrolled over 30,000 Black and White adults from across the United States, has produced some of the most rigorous data on what actually reduces cardiovascular events in Black men. The answer is not exotic — it is aggressive blood pressure control, statin therapy in those with elevated atherogenic particle burden, structured aerobic exercise, and sleep assessment for OSA. These are the same interventions the rest of this book describes. The difference is urgency: the window is shorter, the timeline moves earlier, and the default assumption of “I’m probably fine” is more dangerous for a Black man than for the average-risk White male comparator.

The Nairobi-to-Newark Anchor

I arrived in the United States with a training in medicine and a set of clinical instincts shaped by two different contexts. In Kenya, medicine operates in a community where the doctor knows his patients’ families, where the social context of illness is understood without having to ask, and where the professional has a responsibility to the community that extends beyond the clinical encounter.

In America, I learned cardiology at a level of technical sophistication that I am grateful for every day I step into a catheterization lab. I also learned, quickly, that the categories of “physician” and “patient” in American medicine can function as a wall that prevents the clinical conversation from going where it needs to go. The Black man who sits across from a non-Black physician and does not believe his concerns will be taken seriously is not being paranoid. He is being empirical.

What I can offer, as a cardiologist who has seen both contexts, is this: the shared physiology is more powerful than the different histories. The coronary arteries of a man in Nairobi and a man in Newark run on the same biology. The vascular endothelium does not know citizenship. What varies between them is context, exposure, access, and the cultural armor that men on both continents use to avoid looking directly at their own mortality.

I am not claiming authority over the African American experience. It is not mine to claim. What I can say, from where I stand, is that the data argues for urgency, and the urgency belongs to you more than to anyone who might or might not advocate for you inside the healthcare system. The man who knows his numbers — who walks into the appointment with his ApoB, his Lp(a), his blood pressure trend, and his family history organized — is the man who forces the quality of care he deserves. That is not how it should be. But it is how it is.

Clinical Pearl: Black men in the United States are not more likely to develop coronary artery disease than White men. They are more likely to die from it, to die from it younger — the 1-in-63 risk of cardiometabolic death before age 45 is more than twice the rate of White men — and to have their first clinical presentation be a catastrophic event rather than an incremental warning. The 779,387 excess cardiovascular deaths of Black Americans between 2000 and 2022 represent not fate, but a structural failure of prevention. The clinical response is not different from what this book has recommended throughout: ApoB, Lp(a), coronary artery calcium, blood pressure control, sleep assessment. The difference is timing: the preventive window opens earlier, closes earlier, and requires a physician who understands both the urgency and the context. If you are a Black man who has not had a comprehensive cardiovascular assessment in the last two years, that is the most important sentence this book contains.

Permission Paragraph

You have been carrying two bodies — the one that navigates the world and the one that absorbs what the world costs you. I am not talking about this in the language of politics, though politics is real. I am not talking about this in the language of trauma, though the accumulated stress is real and it has a physiology. I am talking about it in the language of cardiology: the chronic activation of the stress response that accompanies the navigation of a society that was not designed for your success has a measurable signature. It shows up in inflammatory markers. It shows up in blood pressure readings that are elevated at work and lower at home. It shows up in the allostatic load of a man who is excellent at managing the external world and has no safe space to put down what the external world costs him.

You are not required to fix that system. You are required to protect your body within it.

The man who gets his ApoB checked at 38, who gets his Lp(a) measured once and knows what it means, who has his blood pressure properly controlled before the complications announce themselves, who asks his physician directly for the care that the evidence says he needs — that man is not doing something heroic. He is doing something necessary. And he is, in a small but real way, withdrawing from the transaction where the system takes more from him than it gives back.

This chapter is about how.

What to Do This Week

1. Request the following specific tests from your physician or through a direct-access laboratory service: ApoB, Lp(a) (one-time test, does not need to be repeated), hs-CRP, and fasting insulin. These four tests, together with a complete metabolic panel and CBC, provide the most clinically meaningful baseline cardiovascular risk picture that a single blood draw can provide.

2. Measure your blood pressure at home, using a validated upper-arm cuff, twice daily for seven days — once in the morning before caffeine or activity, once in the evening. Average the readings. If the average exceeds 130 mmHg systolic or 80 mmHg diastolic, bring that record to your physician. Do not trust a single office measurement. Do not trust a wrist cuff. Upper-arm, validated device, twice daily, seven days.

3. If you are between 38 and 55, have any family history of premature cardiovascular disease (first-degree male relative with MI, stroke, or cardiac death before 60), or have two or more conventional cardiovascular risk factors, ask your physician specifically about coronary artery calcium scoring. Given the earlier onset of atherosclerosis in Black men, the conventional “start at 45-50” recommendation may need to move to “start at 38-42” in your clinical context.

Transition to Chapter 12

You have now been given the clinical vocabulary of your own cardiovascular risk — the mechanisms, the biomarkers, the behavioral and structural factors, the population-specific urgency. Knowledge is the preparation. The next chapter is what you do with it. Thirty days. Ninety days. Three hundred and sixty-five days. A specific, evidence-graded, cardiologist-designed protocol for the first year of not dying early.

End of Chapters 9, 10, and 11

Sources cited in this section:

• Lehrer PM, Gevirtz R. (2014). Heart rate variability biofeedback. Front Psychol, 5, 756.
• Bayoumy K et al. (2021). Smart wearable devices in cardiovascular care. Nat Rev Cardiol, 18(8), 581–599.
• Shcherbina A et al. (2017). Wearable accuracy in diverse cohort. J Pers Med, 7(2), 3.
• Bent B et al. (2021). Investigating sources of inaccuracy in wearable optical heart rate sensors. NPJ Digit Med, 4, 18.
• Holt-Lunstad J et al. (2015). Loneliness and social isolation as risk factors for mortality. Perspect Psychol Sci, 10(2), 227–237.
• Valtorta NK et al. (2016). Loneliness and social isolation as risk factors for CHD and stroke. Heart, 102(13), 1009–1016.
• Hakulinen C et al. (2018). Loneliness and social isolation as risk factors for CVD. Heart, 106(18), 1394–1399.
• Cacioppo JT et al. (2002). Loneliness and health: Potential mechanisms. Psychosom Med, 64(3), 407–417.
• AHA Presidential Advisory (2023). Social isolation and loneliness and CVD. Circulation.
• U.S. Surgeon General’s Advisory on Loneliness and Isolation (2023). HHS.
• Arun AS, Sawano M, Lu Y et al. (2024). Excess CVD mortality among Black Americans 2000–2022. JACC, 84(6), 581–588.
• PMC11954819 — Cardiometabolic deaths in Black and White men. PMC 2025.
• AHA 2026 Statistical Update: Black Race and CVD Fact Sheet.
• Pencina MJ et al. (2019). Lifetime hypertension risks by race. JAMA Cardiol, 4(6), 587–590.
• Geronimus AT et al. (2006). Weathering and allostatic load. Am J Public Health, 96(5), 826–833.
• Williams DR et al. (2021). Racism and health-care quality. Harvard Scholar.
• IOM Unequal Treatment (2003). NCBI Bookshelf.
• IOM Unequal Treatment 20-year follow-up (2024). NCBI.
• KFF/The Undefeated Survey on Race and Health (2020).
• Pew Research: Black Americans and Mistrust of U.S. Healthcare (2024).
• PMC12154956: Black men’s healthcare use (2025).
• CARDIA Study — AHA Scientific Statement 2017.
• ALLHAT trial. JAMA, 2002.
• WHO AFRO NCD Report (2025).
• CDC High Blood Pressure Facts.
• Association of Black Cardiologists — Cardiology Deserts Initiative.
• Tajeu GS et al. (2022). Disparities in CVD mortality. Circulation, 146(3).